

**Metabolic Endocrine Education Foundation (MEEF)
638 Lindero Canyon Dr Suite # 380
Oak Park, CA 91377**


NONPROFIT
ORG
US POSTAGE PAID
VAN NUYS, CA
PERMIT # 659

Register Online: www.heartindiabetes.com/registration

CME Symposium IN ASSOCIATION WITH THE 10th



EARN
CME
ABIM-MOC
CREDITS
1.75



The DCRM Patient

Friday, June 19, 2026
7:30 pm – 9:15 pm EST
Loews Philadelphia Hotel
Philadelphia, PA

DINNER WILL BE SERVED

All content available ON-DEMAND for ONE YEAR following the meeting.

This is a CME Symposium Supported by an Educational Grant from **AstraZeneca**

Free for all 10th HiD Attendees. Register online www.heartindiabetes.com/registration

JOINTLY PROVIDED



ADMINISTERED BY:





THE DCRM PATIENT

CHAIRS: **Yehuda Handelsman, MD • Stephen J. Greene, MD**

7:30 pm – 9:15 pm	DINNER CME SYMPOSIUM:	Supported by <i>AstraZeneca</i>
7:30 pm	Introduction & Pre-CME Questions	
7:40 pm	Case Presentation: The Complex CRM Patient	Yehuda Handelsman, MD
7:45 pm	Prevention and Management of CRM Complications Focused on Obesity	Neha J. Pagidipati, MD, MPH
8:00 pm	Hard to Control HTN – Is it Resistant HTN?	Raymond R. Townsend, MD
8:15 pm	Kidney Impact on Co-Morbidities Approach to Treatment	Peter Rossing, MD, DMSc
8:30 pm	Addressing Heart Failure in DCRM Diseases	Stephen J. Greene, MD
8:45 pm	Panel Discussion and Q&A: The DCRM Patient – Where to Start?	Yehuda Handelsman, MD
	Panel: Stephen J. Greene, MD, Neha J. Pagidipati, MD, MPH, Peter Rossing, MD, DMSc, Raymond R. Townsend, MD	
	Moderator: Yehuda Handelsman, MD	
9:10 pm	Post-CME Questions & Concluding Remarks	
9:15 pm	Adjourn	

Program Description

Obesity is central in cardiorenal-metabolic (CRM) diseases driving DM, HTN, CKD, HF, MASLD, ASCVD, and cancers- contributing to ~1.6 million premature deaths globally. Evidence increasingly supports incretin-based therapies across CRM conditions. HTN, affecting 1.4 billion adults, with resistant HTN—common in obesity and CKD—posing additional risk. Excess aldosterone drives resistant HTN and kidney fibrosis; novel selective aldosterone synthase inhibitors, alone and with SGLT2 inhibitors, show promise. Integrated, evidence-based strategies are essential across obesity and CRM conditions. This symposium will address the challenges in diagnosis and management of patients with complex & multiple CRM diseases.

Learning Objectives

Upon completion of this CME symposium, participants should be able to:

- Discuss the contributions of obesity to cardiorenal and metabolic comorbidities
- Recognize new pathways and emerging treatment options for hypertension and resistant hypertension
- Explore connection between CKD, HF and other CRM conditions, along with implications for treatment
- Describe the differential diagnosis of cardiomyopathy, HFpEF, and HFrEF and appropriate treatment for each form of HF

Target Audience

This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of CKD and HF and prevention of morbidity and mortality.

FACULTY



Yehuda Handelsman, MD, Chair
FACP, FNLA, FASPC, FAHA, MACE
Medical Director & Principal Investigator
The Metabolic Institute of America
Adjunct Clinical Professor of Medicine,
Charles Drew University, Los Angeles, CA
Chair, Scientific Advisory Board, DCMi—
Diabetes CardioRenal & Metabolism Institute
Tarzana, California



Stephen J. Greene, MD, Chair, FACC, FHSA
Associate Professor of Medicine, Division of Cardiology
Co-Director, Duke Heart Failure Medication
Titration Clinic
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina



Neha J. Pagidipati, MD, MPH
Associate Professor, Division of Cardiology,
Duke University School of Medicine
Director, Duke Cardiometabolic Prevention Clinic
Duke Clinical Research Institute
Durham, North Carolina



Raymond R. Townsend, MD, FAHA
Professor of Medicine
Associate Director
The Clinical and Translational Research Center
University of Pennsylvania
Philadelphia, Pennsylvania



Peter Rossing, MD, DMSc
Professor Department of Clinical Medicine
University of Copenhagen
Steno Diabetes Center Copenhagen
Herlev, Denmark

CME DINNER SYMPOSIUM

This CME Supported Symposium is FREE for 10th HID attendees and will stay on demand for ONE year following the meeting

Learn more at www.heartindiabetes.com/cmесymposium

To register to the entire Heart in Diabetes meeting
please visit www.heartindiabetes.com/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint provider ship of Creighton University and Metabolic Endocrine Education Foundation (MEEF). Creighton Health Sciences Continuing Education (HSCE) is accredited by the ACCME to provide continuing medical education for physicians. Administrated by the Metabolic Institute of America PESI, Inc. designated this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

For more information, please contact: info@tmioa.com or **818.342.1889**

This is a CME program Supported by an Educational Grant from **AstraZeneca**